RxDoctor Payments Data

Gregory Sutton, MD

Ophthalmology · Lincoln, NENPI 1023016656

Payments from drug & device makers

What this record shows

AbbVie accounts for 75.3% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $611, 9.3 times the $66 reported in 2019.

$1,216in general payments, 2019–2025

Across 30 payments — averaging $40.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$915
  • Optos, Inc.$158
  • Amgen$67
  • Tarsus Pharmaceuticals, Inc.$26
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$23
  • Alcon$14
  • plus $13 from 1 others

What the payments were for

  • Speaking & faculty fees$59749%
  • Food & beverage$61951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,216 in reported general payments places this provider in the 65th percentile of 105 ophthalmology providers in Nebraska.

See all ophthalmology providers in Nebraska

Medicare billing

Part B allowed, 2024
$626,798
Medicare patients
1,253
Services billed
4,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost57$23,263
RestasisCyclosporine20$19,093
Latanoprost2,027$18,229
CombiganBrimonidine Tartrate/Timolol34$12,092
Levobunolol Hcl496$10,522
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat611$10,170
Prednisolone Acetate165$6,430
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$6,259
Travoprost41$5,977
SimbrinzaBrinzolamide/Brimonidine Tart18$3,612
Brimonidine Tartrate171$2,615
Dorzolamide Hcl125$2,527
Carteolol Hcl100$2,486
Ketorolac Tromethamine59$1,313
Ofloxacin59$829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$915$54,449111 claims
AlconSimbrinza$14$3,61218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 105 ophthalmology providers in Nebraska.

Other ophthalmology in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →